Supply Chain Intelligence

BeyondSpring Inc. Supply Chain

BYSI supply chain intelligence for BeyondSpring Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

BYSI ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

3Suppliers
11Customers
1Debt Items
20Related Chains

Source-Backed Evidence Depth

BeyondSpring Inc. (BYSI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships
2Distinct source URLs
5High confidence
0.720Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

BeyondSpring Inc. Suppliers

TickerNameConfidenceEvidence
ASYMCHEM-LABORATORIES ASYMCHEM-LABORATORIES 90% We outsource the production of the active pharmaceutical ingredient of Plinabulin to external service providers, Johnson Matthey Pharma Services (JMPS) and Asymchem Laboratories (Asymchem)
BASF-SE BASF-SE 90% We rely on BASF SE as the sole supplier of the stabilizing agent, Kolliphor HS15, used in Plinabulin’s current formulation
PHARMACEUTICS-INTERNATIONAL-INC PHARMACEUTICS-INTERNATIONAL-INC 90% and the production of the final drug formulation to Pharmaceutics International Inc. (Pii) and for contingency planning purposes, we have also established relationships with other contract manufactur…

BeyondSpring Inc. Customers

TickerNameConfidenceEvidence
LLY Eli Lilly and Company 72% s based on net sales of the Plinabulin Products, which sets forth minimum royalties to be received by Wanchunbulin for a specified period. The Hengrui Collaboration Agreement is within the scope of A…
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from BYSI graph: s based on net sales of the Plinabulin Products, which sets forth minimum royalties to be received by Wanchunbulin for…
CAPITAL-RESOURCES CAPITAL-RESOURCES 62% cal studies and development activities; ● costs associated with regulatory operations; ● costs associated with protecting intellectual property; ● other expenses, which include direct and allocated e…
CORPORATE-INFORMATION-BEYONDSPRING-INC CORPORATE-INFORMATION-BEYONDSPRING-INC 62% al controller, have committed relevant crimes such as corruption, bribery, embezzlement, misappropriation of property or undermining the order of the socialist market economy during the latest three …
CT-CORPORATION CT-CORPORATION 62% al controller, have committed relevant crimes such as corruption, bribery, embezzlement, misappropriation of property or undermining the order of the socialist market economy during the latest three …
JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD 62% the Company will sell and transfer to the Purchasers a total of 3,500,128 Shares, comprised of 1,750,064 Shares to Winning View Investment Limited, 583,355 Shares to FULL TECH CORPORATE DEVELOPMENT L…
MAPFIL-INVESTMENT-LIMITED MAPFIL-INVESTMENT-LIMITED 62% the Company will sell and transfer to the Purchasers a total of 3,500,128 Shares, comprised of 1,750,064 Shares to Winning View Investment Limited, 583,355 Shares to FULL TECH CORPORATE DEVELOPMENT L…
PHARMACEUTICS-INTERNATIONAL-INC PHARMACEUTICS-INTERNATIONAL-INC 62% al controller, have committed relevant crimes such as corruption, bribery, embezzlement, misappropriation of property or undermining the order of the socialist market economy during the latest three …
SEED-TECHNOLOGY-LIMITED SEED-TECHNOLOGY-LIMITED 62% so, with the grant of status as a 2017 National Science and Technology Major Project in China, or the 2017 Grant, Plinabulin has been included in the National Drug Priority Review List. We believe th…
WINNING-VIEW-INVESTMENT-LIMITED WINNING-VIEW-INVESTMENT-LIMITED 62% the Company will sell and transfer to the Purchasers a total of 3,500,128 Shares, comprised of 1,750,064 Shares to Winning View Investment Limited, 583,355 Shares to FULL TECH CORPORATE DEVELOPMENT L…
WINNING-VIEW-INVESTMENTS-LIMITED WINNING-VIEW-INVESTMENTS-LIMITED 62% d. 8 BEYONDSPRING INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Amounts in thousands of U.S. Dollar (“$”) and Renminbi (“RMB”), except for number of shares and per share data) (Unaud…

BeyondSpring Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
BYSI-DEBT Debt stack $246,000 90% Market cache reports total debt of $246,000.

BeyondSpring Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for BeyondSpring Inc..

BeyondSpring Inc. Ownership

HolderNameConfidenceEvidence
BYSI-OWNER-DECHENG-CAPITAL-LLC Decheng Capital LLC 90% 13F overlay lists Decheng Capital LLC as top holder; 23 tracked holders.

BeyondSpring Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ACIU AC Immune SA 100.00 2
INCY Incyte Corporation 100.00 2
ALEC Alector, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
FDMT 4D Molecular Therapeutics, Inc. 100.00 2
IMNM Immunome, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
VEEV Veeva Systems Inc. 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
ACRS Aclaris Therapeutics, Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
CRIS Curis, Inc. 100.00 2
NVO Novo Nordisk A/S 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AKTS Aktis Oncology, Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
IVA Inventiva S.A. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for BeyondSpring Inc..

Unlock full BYSI data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
BYSI
Unlock BYSI Supply Chain Data
Verified relationships include:
ASYMCHEM-LABORATORIESASYMCHEM-LABORATORIESSupplier90%
BASF-SEBASF-SESupplier90%
LLYEli Lilly and CompanyCustomer72%
LLYEli Lilly and CompanyCustomer72%
+12 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →